Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Ostex International Inc.

(OSTX)

Business: Metabolic/Bone disorders

Vector Securities International analyst Peter Ginsberg said the signing

Read the full 166 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE